Goldman Sachs Group set a GBX 6,000 ($78.93) price objective on AstraZeneca (LON:AZN) in a report released on Thursday, Borsen Zeitung reports. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.
Several other equities analysts have also recently weighed in on the company. Credit Suisse Group boosted their price objective on AstraZeneca from GBX 8,200 ($107.87) to GBX 8,500 ($111.81) and gave the stock an outperform rating in a research report on Thursday, January 16th. Bank of America reissued a buy rating and set a GBX 8,500 ($111.81) price objective on shares of AstraZeneca in a research report on Tuesday, October 8th. Liberum Capital boosted their price objective on AstraZeneca from GBX 8,300 ($109.18) to GBX 8,810 ($115.89) and gave the stock a buy rating in a research report on Wednesday. Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Monday, January 13th. Finally, Jefferies Financial Group set a GBX 7,475 ($98.33) price objective on AstraZeneca and gave the stock a neutral rating in a research report on Wednesday. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of Buy and an average target price of GBX 7,912.14 ($104.08).
Shares of LON AZN traded up GBX 2 ($0.03) during trading hours on Thursday, hitting GBX 7,659 ($100.75). 1,513,424 shares of the company’s stock were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 109.51 ($1.44) and a 1-year high of £727.50 ($956.99). The company has a debt-to-equity ratio of 148.59, a current ratio of 0.92 and a quick ratio of 0.70. The stock has a market capitalization of $100.55 billion and a price-to-earnings ratio of 48.05. The company’s 50-day moving average price is GBX 7,597.76 and its 200-day moving average price is GBX 7,212.91.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.